Clinical significance of colonic intraepithelial lymphocytosis in a pediatric population

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Modern Pathology (Impact Factor: 6.19). 02/2009; 22(1):13-20. DOI: 10.1038/modpathol.2008.139
Source: PubMed


The significance of colonic intraepithelial lymphocytosis has been well described in adults, and is associated with lymphocytic colitis, untreated celiac disease, and medications, among others. Little is known about the meaning of colonic intraepithelial lymphocytosis in the pediatric population; this study examines this finding in a cohort of children. Twenty patients in whom colonic intraepithelial lymphocytosis was a prominent feature were identified from 1999 to 2005. Colonic intraepithelial lymphocytosis was defined as 20 or more intraepithelial lymphocytes per 100 colonocytes present in at least one colonic mucosal biopsy. Each biopsy was examined for numbers of intraepithelial lymphocytes per 100 surface and crypt colonocytes; various architectural, inflammatory, and metaplastic changes were also noted. When available, concurrent duodenal and/or ileal biopsies were examined. Studied clinical parameters included indications for biopsy, clinical follow-up, final diagnosis, comorbidities, autoimmune serologies, and medications. A total of 121 colonic mucosal biopsies were examined in 20 patients who ranged from 1 to 17 years (mean 10.2 years; 40% male). Common indications for endoscopy included diarrhea and abdominal pain. A mean of 29 (+/-22) intraepithelial lymphocytes per 100 enterocytes were seen. Seven patients had colonic intraepithelial lymphocytosis as the only histologic finding. The remaining 13 patients had additional architectural, inflammatory, and metaplastic changes. The mean follow-up period was 14 months (range 1-48 months). Inflammatory bowel disease was diagnosed in 4 of 20 patients and was seen chiefly in biopsies in which colonic intraepithelial lymphocytosis was associated with architectural or inflammatory changes. Common disease associations include celiac disease, lymphocytic colitis, and autoimmune enteropathy. Pediatric colonic intraepithelial lymphocytosis, in the absence of other histologic findings, is associated with various diseases, including celiac disease, lymphocytic colitis, and autoimmune enteropathy. Colonic intraepithelial lymphocytosis in the presence of other inflammatory changes indicates the possibility of idiopathic inflammatory bowel disease. These findings are similar to those seen in adults, with the exception of autoimmune enteropathy.

Download full-text


Available from: Robert Najarian, May 29, 2014
71 Reads
  • The American Journal of Gastroenterology 07/2011; 106(7):1367-8. DOI:10.1038/ajg.2011.91 · 10.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphocytic colitis (LC) and collagenous colitis (CC), 2 histologic forms of microscopic colitis, were recognized as rare disease entities 4 decades ago. An increasing body of evidence accumulated in the past 40 years reveals increasing incidence and prevalence rates, a wide spectrum of clinical presentations, and several histologic variants. Although several recent randomized clinical trials confirmed the efficacy of oral budesonide in treating LC and CC, disease relapse after a short-duration treatment is common. Despite their common clinical presentations and well-defined histologic diagnostic criteria, there are only few studies on the immunologic abnormalities in colonic tissue. The aim of this review is to (1) familiarize the pathologists in general practice with histomorphology of LC and CC, including the rare histologic variants and the clinical implication associated with these 2 diagnoses, (2) summarize the data from recent randomized clinical trials of oral budesonide, and (3) review immunological studies on colonic tissue. Overall, immunologic abnormalities of colonic tissue seem to explain for the histomorphologic features and the clinical symptomatology of LC and CC. Advances in the understanding of the underlying immunologic abnormalities in the colonic tissue may help develop novel and effective therapies for these 2 diseases.
    Advances in anatomic pathology 01/2012; 19(1):28-38. DOI:10.1097/PAP.0b013e31823d7705 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microscopic colitis (MC) is prevalent in adults investigated for chronic watery diarrhea, yet characterization of pediatric MC is limited. Our pathology database was searched from 1995 to 2011 for pediatric cases of lymphocytic colitis (LC) or collagenous colitis (CC). Those with diarrhea > 2 weeks and visually normal colonoscopy were accepted as cases. Demographics, lab results, medication use within 3 months of presentation, past medical and family history of autoimmune disease, and response to treatment were abstracted. Twenty-seven cases were histologically consistent with MC on biopsy; 5 with concomitant enteric infection or isolated abdominal pain were excluded. Twenty-two cases of MC (female, 59%; median age at diagnosis, 15.3 years) were included (19 LC and 3 CC). Two had type 1 DM, two were ANA positive, and two had CVID. Of 20 patients who underwent an EGD, one had collagenous sprue and 4 had celiac disease. One presented after clearance of recurrent Clostridium difficile infection. Prior drug exposures included: NSAIDs (n = 7), PPIs (n = 6), and SSRIs (n = 3). Common symptoms in addition diarrhea included abdominal pain (77.3%) and weight loss (27.3%). Of 17 patients with follow-up, all 8 treated with steroids had some response; 57.1% (4/7) responded to mesalamine, and 42.9% (3/7) responded to bismuth subsalicylate. In this cohort of pediatric patients, LC was much more common than CC. As described in adults, we observed associations with celiac disease, type 1 DM, and medications; we additionally saw an association with immunodeficiency. Our patients showed greater response to steroids than mesalamine or bismuth.
    Journal of pediatric gastroenterology and nutrition 06/2013; 57(5). DOI:10.1097/MPG.0b013e3182a1df59 · 2.63 Impact Factor
Show more